fingolimod hydrochloride has been researched along with Coxsackie Virus Infections in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R; Ge, J; Li, M; Liu, G; Wang, X; Yu, Y; Zou, Y | 1 |
1 other study(ies) available for fingolimod hydrochloride and Coxsackie Virus Infections
| Article | Year |
|---|---|
FTY720 alleviates coxsackievirus B3-induced myocarditis and inhibits viral replication through regulating sphingosine 1-phosphate receptors and AKT/caspase-3 pathways.
Topics: Animals; Antiviral Agents; Apoptosis; Caspase 3; Cells, Cultured; Coxsackievirus Infections; Disease Models, Animal; Enterovirus B, Human; Fingolimod Hydrochloride; Host-Pathogen Interactions; Male; Mice, Inbred BALB C; Myocarditis; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Time Factors; Virus Replication | 2019 |